CO4520295A1 - FUSION PROTEIN - Google Patents

FUSION PROTEIN

Info

Publication number
CO4520295A1
CO4520295A1 CO96060058A CO96060058A CO4520295A1 CO 4520295 A1 CO4520295 A1 CO 4520295A1 CO 96060058 A CO96060058 A CO 96060058A CO 96060058 A CO96060058 A CO 96060058A CO 4520295 A1 CO4520295 A1 CO 4520295A1
Authority
CO
Colombia
Prior art keywords
fusion protein
same
fas
hfasl
gloss
Prior art date
Application number
CO96060058A
Other languages
Spanish (es)
Inventor
Thomas Buehler
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ag filed Critical Sandoz Ag
Publication of CO4520295A1 publication Critical patent/CO4520295A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

UNA PROTEINA DE FUSION QUE COMPRENDE EL LIGANDO FAS HUMANO (HFASL) O UN FRAGMENTO 5 DEL MISMO O UNA VARIANTE FUNCIONALMENTE EQUIVALENTE DEL MISMO QUE TIENE LAS PROPIEDADES DE UNION DE FAS Y, UNIDO DE MANERA DIRECTA O INDIRECTA A SU PARTE C TERMINA UN GLICOFOSFOLIPIDO LA CUAL ES UTIL PARA EVITAR O TRATAR EL RECHAZO 10 DE INJERTO O DE ORGANO.A FUSION PROTEIN THAT INCLUDES THE HUMAN FAS LINK (HFASL) OR A FRAGMENT 5 OF THE SAME OR A FUNCTIONALLY EQUIVALENT VARIANT OF THE SAME THAT HAS THE PROPERTIES OF UNION OF FAS AND, UNITED DIRECTLY OR INDIRECT TO ITS PART C GLOSS WHAT IS USEFUL TO AVOID OR TREAT REJECTION 10 OF GRAFT OR ORGAN.

CO96060058A 1995-11-16 1996-11-14 FUSION PROTEIN CO4520295A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9523469.6A GB9523469D0 (en) 1995-11-16 1995-11-16 Organic compounds

Publications (1)

Publication Number Publication Date
CO4520295A1 true CO4520295A1 (en) 1997-10-15

Family

ID=10784000

Family Applications (1)

Application Number Title Priority Date Filing Date
CO96060058A CO4520295A1 (en) 1995-11-16 1996-11-14 FUSION PROTEIN

Country Status (10)

Country Link
EP (1) EP0879285A1 (en)
JP (1) JP2000500336A (en)
CN (1) CN1202200A (en)
AU (1) AU7684896A (en)
BR (1) BR9611734A (en)
CA (1) CA2232876A1 (en)
CO (1) CO4520295A1 (en)
GB (1) GB9523469D0 (en)
WO (1) WO1997018307A1 (en)
ZA (1) ZA969623B (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544523B1 (en) * 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
GB9705744D0 (en) * 1997-03-20 1997-05-07 Davies Alison M Methods for selecting cells and their uses
US6972323B1 (en) 1997-04-01 2005-12-06 Sankyo Company, Limited Anti-Fas antibodies
IL123888A0 (en) * 1997-04-01 1998-10-30 Sankyo Co Anti-fas antibodies
US6451759B1 (en) * 1998-01-14 2002-09-17 The Regents Of The University Of California Noncleavable Fas ligand
AU2880400A (en) * 1999-02-12 2000-08-29 Amgen, Inc. Tnf-related proteins
GB9905503D0 (en) 1999-03-10 1999-05-05 Adprotech Plc Novel compound formulations and methods of delivery
DE60127933T2 (en) * 2000-01-03 2008-02-07 Mark L. Merion Station Tykocinski CHIMERIC PROTEINS AND APPLICATIONS
CA2396979C (en) * 2000-01-24 2015-07-14 University Of Louisville Research Foundation, Inc. Immune modulation with death receptor-induced apoptosis
US7927602B2 (en) 2002-07-23 2011-04-19 University Of Louisville Research Foundation, Inc. Fas ligand-avidin/streptavidin fusion proteins
AU1676302A (en) 2000-06-30 2002-01-14 Univ Louisville Res Found Alteration of cell membrane for new functions
CN103153332A (en) 2010-09-28 2013-06-12 卡尔医疗有限公司 Compositions and methods for treatment of hematological malignancies
WO2018152451A1 (en) * 2017-02-17 2018-08-23 Purdue Research Foundation Targeted ligand-payload based drug delivery for cell therapy
AU2018230474B2 (en) * 2017-03-10 2023-08-03 Georgia Tech Research Corporation FasL-engineered biomaterials with immunomodulatory function

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6237145U (en) * 1985-08-23 1987-03-05
US5223408A (en) * 1991-07-11 1993-06-29 Genentech, Inc. Method for making variant secreted proteins with altered properties
JPH0590011A (en) * 1991-09-26 1993-04-09 Anritsu Corp Thermosensitive resistor and its manufacture
JPH05332845A (en) * 1992-06-03 1993-12-17 Kobe Steel Ltd Output conversion method and device of temperature detector
DE69535719T2 (en) * 1994-01-07 2009-03-19 Mochida Pharmaceutical Co. Ltd. FAS-ANTIGEN-BINDING LIGAND

Also Published As

Publication number Publication date
CA2232876A1 (en) 1997-05-22
EP0879285A1 (en) 1998-11-25
CN1202200A (en) 1998-12-16
ZA969623B (en) 1998-05-15
GB9523469D0 (en) 1996-01-17
AU7684896A (en) 1997-06-05
WO1997018307A1 (en) 1997-05-22
JP2000500336A (en) 2000-01-18
BR9611734A (en) 1999-02-23

Similar Documents

Publication Publication Date Title
CO4520295A1 (en) FUSION PROTEIN
CL2009002139A1 (en) Synthetic peptide comprising the sequence sec id no: 6 and sec id no: 7 of the hiv virus gp41 protein with antiretroviral activity.
ES2186796T3 (en) PROCEDURE FOR THE TREATMENT OF ALLERGIC ASTHMA.
DE69837855D1 (en) APOLIPOPROTEIN A-I AGONISTS AND THEIR APPLICATION FOR THE TREATMENT OF DYSLIPIDARY DISEASE
NL300195I1 (en) Synergistic combinations of zidovudine, 1592U89 and 3TC or FTC.
ES2077666T3 (en) BINDING PROTEIN TO FIBRONECTIN AND ITS PREPARATION.
DE69524389T2 (en) 6-SUBSTITUTED MYCOPHENOLIC ACID DERIVATIVES WITH IMMUNE SUPPRESSIVE EFFECT
AR004357A1 (en) 1-PHENYL-2-DIMETHYLAMINOMETHYL-CYCLOHEXAN-1-OL COMPOUNDS, AND PREPARATION PROCEDURE FOR SUCH COMPOUNDS.
DE69626660T2 (en) 2-alkylpyrrolidines
EA200000445A1 (en) METHODS OF TREATING THE CONDITION OF HYPERCOAGULATION OR ACQUIRED INSUFFICIENCY OF PROTEIN C
DE69730038D1 (en) SOLUBLE MONOVALENTS AND MULTIVALENTS MHC CLASS II FUSION PROTEINS AND THEIR USE
ATE320488T1 (en) MUTANTS OF THE LAG-3 PROTEIN, THEIR EXPRESSION AND USE
ES2079481T3 (en) A PROCEDURE FOR THE DETERMINATION OF THE FUNCTIONAL ACTIVITY OF PROTEIN S OR FREE PROTEIN C IN A PLASMA SAMPLE.
DE3781392D1 (en) CLOTHING THAT ENSURES GOOD HUMIDITY EXHAUST.
ES2007305B3 (en) COMBINATION OF CLOTHES
ES2148283T3 (en) GEN MERLIN TUMOR SUPPRESSOR AND USES OF THE SAME.
DE69120390D1 (en) Collagen-binding protein and its production
FI973184A0 (en) Combination therapy for HIV infection with the HIV protease inhibitor Indinavir and the reverse transcriptase inhibitor 3TC, possibly in combination with AZT, DDI or DDC
DK1037642T3 (en) Modified polysaccharides with altered biological recognition
ES2162427T3 (en) DILUYENTE DE ESPERMA THAT INCLUDES NATURAL PHOSPHOCASEINATE OR BETA-LACTOGLOBULIN, ITS PREPARATION PROCEDURE AND ITS USES.
ECSP961934A (en) LIGANDO FAS FUSION PROTEIN
IT1238301B (en) PROCEDURE FOR THE REALIZATION OF FOOTWEAR AND FOOTWEAR OBTAINED WITH THIS PROCEDURE.
DE69720275D1 (en) THE MORPHOGENIC PEPTIDE CALLED RECOVERY OF TISSUE TISSUE
ES2063161T3 (en) MODIFIED PROTEINS.
ES2129047T3 (en) METHOD TO IMPROVE MEMORY AND QUALITY OF LIFE.